Organic compounds
AssigneeNovartis AG
InventorsMichael AMBUHL, Jutta BEYER, Begona CARRENO-GOMEZ, Colleen RUEGGER, Stephen VALAZZA
Life of this patent
Estimating the term…
Abstract
The present invention provides various pharmaceutical compositions comprising an S1P receptor modulator, e.g. an S1P receptor agonist. In one aspect, there is provided a pharmaceutical composition having a coating. In other aspects, rapid disintegrating compositions are provided. In a further aspect, a pharmaceutical composition which is free of sugar alcohols is provided. In another aspect, the invention provides a pharmaceutical composition comprising a coating comprising an S1P receptor modulator.
Claims59
An oral pharmaceutical composition comprising an S1P receptor modulator, wherein the composition comprises a coating comprising:
- (a) one or more polymer resins
- (b) one or more metal oxides.
A fast disintegrating solid pharmaceutical composition comprising:
- (a) an S1P receptor modulator
- (b) an alkaline earth metal silicate
- (c) a disintegration agent
- wherein the ratio of the silicate:disintegration agent is from 2:1 to 10:1
A rapid disintegrating pharmaceutical composition comprising a freeze dried dosage form of an S1P receptor modulator.
A solid pharmaceutical composition suitable for oral administration, comprising:
- (a) an S1P receptor modulator;
- and
- (b) a microcrystalline cellulose
- in the absence of a sugar alcohol.
A pharmaceutical composition which comprises a coating comprising an S1P receptor modulator.
A process for producing a pharmaceutical composition, comprising
- (a) mixing a freeze dried dosage form of an S1P receptor modulator with a structure forming agent;
- (b) producing an aqueous suspension, wherein the aqueous suspension contains less than 50% solid;
- and
- (c) optionally further conducting a lyophilisation step.
Dependencies are inferred from the claim text.